IRVINE, California and REHOVOT, Israel, June 17, 2016 /PRNewswire/ -- OticPharma, Ltd., a privately held specialty pharmaceutical company focused on acquiring and developing innovative therapies for ear, nose, and throat (ENT) disorders, today announced that Gregory J. Flesher, chief executive officer, will present at the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016 at 11:00 AM EDT at the St. Regis New York.

Logo - http://photos.prnewswire.com/prnh/20150902/263275LOGO

About OticPharma

OticPharma is a clinical-stage pharmaceutical company focusing on the acquisition and development of ear, nose, and throat (ENT) products that restore health and address unmet needs in children and adults.  The company's proprietary foam technology (OP-01) is currently being developed for acute otitis externa ("swimmers ear") and is also being explored for the treatment of nasal and sinus conditions.  The company's proprietary surfactant technology (OP-02) is currently being developed as a potential first-in-class, antibiotic-free treatment option for acute, recurrent, and chronic otitis media.

Investor and Media Contact
Gita Ogawa
The Trout Group
Gogawa@troutgroup.com
Tel: +1 (646) 378-2949

Company Contact
Gregory J. Flesher
OticPharma, Ltd.
gflesher@oticpharma.com
Tel: +1 (949) 238-8090

Related Links

http://www.oticpharma.com

SOURCE OticPharma, Ltd.